Zanoprima Launches Commercial Production of Its High Purity Tobacco-Free Synthetic (S) Nicotine Using Revolutionary Patented New Process
11.10.2021 13:13:00 EEST | Business Wire | Press release
Zanoprima Lifesciences (www.zanoprima.com) (https://www.linkedin.com/company/zanoprima/) a UK based company, announced commercial production of its high purity synthetic (S)-Nicotine (SyNic) using a revolutionary patented process that does not involve the use of tobacco or any synthetic racemic mixture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005296/en/
Zanoprima's tobacco-free high purity synthetic (S) Nicotine is SyNic (Graphic: Business Wire)
This is a landmark development for the trillion-dollar tobacco industry and its 1.3 billion consumers as it heralds the arrival of a superior, substantially lower-risk, cost-effective, and greener alternative to a global industry that is arguably the single biggest avoidable cause of death globally.
Zanoprima has developed and patented the process to manufacture high purity (typically 99.9%), synthetic (S)-Nicotine (SyNic) for commercial use that is free of TSNA (tobacco-specific Nitrosamines), toxins, carcinogens, odour, and harsh taste. Zanoprima offers the entire range of products including SyNic (S)-Nicotine Bitartrate (Nicotine Bitartrate Dihydrate), SyNic (S)-Nicotine polacrilex resin/Nicotine resinate and its novel proprietary (S)-Nicotine complex.
SyNic (S)-Nicotine conforms to and exceeds European Pharmacopeia (EP) and United States Pharmacopeia (USP) specifications. “Green Chemistry” principles compliant production process minimizes the environmental impacts of nicotine production. Applications include:
SyNic Protonated (S)-Nicotine e-liquid for e-cigarettes is without any potentially harmful ingredients such as organic acids and propylene glycol. It is pure, stable and has a long shelf life. E-cigarettes that use SyNic offer a smooth taste and enhanced nicotine experience, a distinct advantage given the nicotine limit guidelines/rules in e-liquids in the EU and other geographies.
Znus: Tobacco-free white snus is completely sodium and tobacco free, delivering a smooth taste without the characteristic odour and harshness of natural nicotine. It has an instant burst followed by sustained release as desired by the traditional Snus users.
Next-gen chewing gum and lozenges that are sodium free offer unique characteristics, providing an instant burst and sustained release of nicotine that users seek. These gums and lozenges contain a new proprietary nicotine complex with superior bioavailability and taste.
Forthcoming launches: Tobacco free heated nicotine products unlike existing tobacco-based Heat Not Burn products and skin friendly transdermal patches for Alzheimer’s and dementia.
Global Patents: Zanoprima owns patent applications or registration for its revolutionary manufacturing process in all major geographies including United States, Europe, Great Britain, Australia, China, India, and others.
As a responsible synthetic nicotine (SyNic) manufacturer Zanoprima will distribute SyNic in strict compliance with regulations in each of its markets, globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005296/en/
Contact information
Ashok Narasimhan
Zanoprima Lifesciences
ashok@zanoprima.com
+44-20-8863 1303
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Achieves SAP® Silver Partner Status in the SAP® PartnerEdge® Program, Expanding SAP Capabilities for European Enterprises30.6.2026 09:00:00 EEST | Press release
FPT announced today that it has achieved SAP silver partner status in the SAP® PartnerEdge® program, recognizing the company's proven customer success, differentiated SAP offerings, and ongoing commitment to SAP certifications. The recognition reflects FPT's growing presence in Europe for SAP technology ecosystems and its experience supporting leading enterprises, including E.ON, RWE, and IONITY, across SAP transformation, application management, and integration initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629805729/en/ Through its SAP practice in Europe, FPT provides organizations with comprehensive SAP capabilities designed to support business transformation and maximize the value of their SAP investments, including: End-to-end SAP services spanning consulting, implementation, integration, migration, optimization, application management, and managed services. SAP software licensing and lifecycle support,
Regnology Launches Regnology Risk Hub (RRiH) Ascend to Deliver Governed, AI Powered Intelligence to Balance Sheet and Enterprise Risk Management30.6.2026 09:00:00 EEST | Press release
Regnology, a global leading provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the launch of Regnology Risk Hub (RRiH) Ascend, the next evolution of the Regnology Risk Hub (RRiH), now fully integrated into the Ascend platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629063140/en/ Designed to help financial institutions move from reactive risk monitoring to proactive decision-making, RRiH Ascend leverages the combined expertise of the acquired OneSumX for Risk solution from Wolters Kluwer and Moody’s regulatory reporting & ALM solutions, bringing together comprehensive risk coverage, advanced analytics and governed intelligence in a single, cloud-native platform. The solution delivers integrated, enterprise-wide coverage across asset-liability management (ALM), liquidity management, market and credit risk, profitability, stress testing and prudential risk, providing
In Line With the LEAP | 28 Portfolio Rotation Strategy, Bureau Veritas Signs an Agreement to Sell Its Oil & Petrochemicals and Coal Testing and Inspection Business30.6.2026 08:30:00 EEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces that it has entered exclusive negotiations with Triton Partners regarding the sale of its Oil & Petrochemicals and Coal testing and inspection business. This strategic divestment is in full alignment with the Group’s LEAP | 28 strategy. The proposed transaction would include the Oil & Petrochemicals and Coal testing and inspection activities. In 2025, this business generated approximately EUR 450 million in revenue operating a global network across multiple countries, with a significant footprint of operational sites and employees. This business grew at a lower rate than the Group and is margin dilutive. It is included within Bureau Veritas’ “Optimize value and impact” portfolio and reported under the Agri-Food & Commodities division. The transaction supports the strategic objective to increase exposure to higher growth and margin businesses. A key milestone in LEAP | 28 portfolio rotati
Corient Accelerates European Growth With the Addition of Letus Private Office30.6.2026 08:15:00 EEST | Press release
Corient today announced an agreement to acquire Letus Private Office (“Letus”), an independent multi-family office and wealth advisory firm serving entrepreneurs, founders and other ultra-high-net-worth individuals and families across France and Europe. The acquisition, subject to closing, builds on recent transactions that have made Corient the world’s largest multi-family office and non-bank wealth manager focused on ultra-high-net worth and high-net-worth clients. Paris-based Letus was founded in 2016 and is led by Managing Partners Anice Chlagou, Stephen Lasry and Alexandre Tsouli, and Partner Sacha Levy. It manages and administers approximately €4.1 billion (about US$5 billion). Letus serves ultra-high-net worth clients, primarily entrepreneurs and their families, providing comprehensive, bespoke services that integrate all aspects of wealth management and family office functions, including investment management, wealth and estate planning, financing, legal and tax support, and ph
Hengrui’s Heng Yi ® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease30.6.2026 08:00:00 EEST | Press release
Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free platform technology, announce today that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629052295/en/ Heng Yi Heng Yi® is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol® platform technology, following the approval of Heng Qin® (perfluorohexyloctane ophthalmic solution) in 202
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
